Get the Stockscreener App
4.28
4.14%
0.17
After Hours:
4.42
0.14
+3.27%
Arbutus Biopharma Corp stock is traded at $4.28, with a volume of 716.78K.
It is up +4.14% in the last 24 hours and down -4.04% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.11
Open:
$4.15
24h Volume:
716.78K
Relative Volume:
0.69
Market Cap:
$820.47M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-9.7273
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
-1.38%
1M Performance:
-4.04%
6M Performance:
+36.31%
1Y Performance:
+10.31%
1-Day Range:
$4.10
$4.30
1-Week Range:
$4.10
$4.535
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.28 | 787.88M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Can Arbutus Biopharma Corporation stock deliver surprise earnings beatJuly 2025 Review & Risk Controlled Swing Trade Alerts - newser.com
What institutional flow reveals about Arbutus Biopharma CorporationJuly 2025 Momentum & Low Risk Investment Opportunities - newser.com
Arbutus Biopharma to Present New Data on Imdusiran and AB-101 at AASLD 2025 - MyChesCo
Is Arbutus Biopharma Corporation stock a buy on dipsMarket Rally & Safe Entry Trade Reports - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageWhat's Next? - MarketBeat
Risk adjusted return profile for Arbutus Biopharma Corporation analyzedPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Arbutus Announces Four Abstracts Accepted for Presentation at AASLDThe Liver Meeting® 2025 - GlobeNewswire
Arbutus Biopharma (ABUS) Showcases Promising Liver Disease Resea - GuruFocus
Has Arbutus Biopharma Corporation formed a bullish divergenceQuarterly Trade Report & Technical Pattern Recognition Alerts - newser.com
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? - Yahoo Finance
Applying Wyckoff theory to Arbutus Biopharma Corporation stockWeekly Trend Report & Fast Gain Stock Tips - newser.com
Is Arbutus Biopharma Corporation forming a reversal pattern2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - newser.com
Risk vs reward if holding onto Arbutus Biopharma CorporationRate Cut & Real-Time Volume Analysis - newser.com
Statistical indicators supporting Arbutus Biopharma Corporation’s strengthWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Voya Investment Management LLC Sells 4,534 Shares of Arbutus Biopharma Corporation $ABUS - Defense World
Will Arbutus Biopharma Corporation stock deliver better than expected guidanceShort Setup & Long Hold Capital Preservation Plans - newser.com
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Assenagon Asset Management S.A. Makes New $122,000 Investment in Arbutus Biopharma Corporation $ABUS - Defense World
Is Arbutus Biopharma Corporation reversing from oversold territoryJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
Arbutus Biopharma Corporation Stock Analysis and ForecastEarnings Miss Alerts & Easy Tools to Analyze Your Investment Risk - earlytimes.in
Does Arbutus Biopharma Corporation fit your quant trading modelJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Can machine learning forecast Arbutus Biopharma Corporation recoveryJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Building trade automation scripts for Arbutus Biopharma Corporation2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
What MACD signals say about Arbutus Biopharma Corporation2025 Historical Comparison & Stepwise Trade Signal Implementation - newser.com
Analyzing drawdowns of Arbutus Biopharma Corporation with statistical tools2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
What machine learning models say about Arbutus Biopharma Corporation2025 Key Lessons & AI Based Buy/Sell Signal Reports - newser.com
Arbutus Biopharma Corporation stock volume spike explainedQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Is Arbutus Biopharma Corporation stock bottoming outLong Setup & Weekly Setup with ROI Potential - newser.com
what machine learning models say about arbutus biopharma corporationJuly 2025 PreEarnings & Risk Controlled Daily Plans - newser.com
Using economic indicators to assess Arbutus Biopharma Corporation potential2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
Aug Setups: Whats next for Arbutus Biopharma Corporation stockLong Setup & Weekly Breakout Watchlists - خودرو بانک
Goldman Sachs Group Inc. Raises Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
Reversal indicators forming on Arbutus Biopharma Corporation stockQuarterly Growth Report & Fast Entry Momentum Trade Alerts - newser.com
Aug Rallies: Is Arbutus Biopharma Corporation stock a top performer YTD2025 Price Action Summary & Technical Pattern Based Signals - خودرو بانک
RSI Check: Should I set a stop loss on RELYMarket Performance Report & Free Community Consensus Stock Picks - خودرو بانک
Arbutus: IP Drama With High Stakes (NASDAQ:ABUS) - Seeking Alpha
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):